Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest Cash

by Monica Gerson, Benzinga Staff Writer

July 2, 2012 2:10 AM | 1 min read | Make a Comment

Below are the top mid-cap biotechnology stocks on the NYSE and the NASDAQ in terms of cash. Illumina

ILMN

had $1.27 billion in total cash and $815.97 million in total debt for the latest quarter. Onyx Pharmaceuticals

ONXX

had $599.99 million in total cash and $165.64 million in total debt for the latest quarter. Human Genome Sciences

HGSI

had $471.80 million in total cash and $821.50 million in total debt for the latest quarter. VIVUS

VVUS

had $333.40 million in total cash and no debt for the latest quarter.

Posted In: Trading Ideas Biotechnology Industry highest cash Mid-Cap

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.